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Xing-hua Chen,1 Cheng Zhang,1 Xi Zhang,1 Li Gao,1 Lei Gao,1 Pei-yan Kong,1 Xian-gui Peng,1
De-guang Qi,2 Ai-hua Sun,1 Dong-feng Zeng,1 Hong Liu,1 Yi Gong,1 Qing-yu Wang1The main obstacle for allogeneic transplantation is delayed hematologic reconstitution and serious graft-ver-
sus-host disease (GVHD). The results of 128 patients with hematologic malignancies undergoing HLA-
identical (n 5 52) or HLA-haploidentical/mismatched (n 5 76) hematopoietic stem cell transplantation
(HSCT) performed during the same time period were compared. Patients with HLA-identical HSCTreceived
unmanipulated granulocyte-colony stimulating factor-mobilized peripheral blood stem cells (G-PBSCs).
Forty-six patients with HLA-haploidentical related HSCT received antithymocyte globulin (ATG) in condi-
tioning regimens followed by the transplantation of the combination of unmanipulated G-PBSCs and granu-
locyte-colony stimulating factor-mobilized bone marrow (G-BM) and 30 patients with HLA-mismatched
unrelated HSCT received ATG in conditioning regimens followed by the transplantation of unmanipulated
G-PBSCs. All patients got successful hematopoietic engraftment. The cumulative incidences of grades I to
II acute GVHD (aGVHD) on day 100 in the identical, haploidentical related and mismatched unrelated
cohorts were 21.2%, 43.5%, and 53.3%, respectively. The cumulative incidences of chronic GVHD (cGVHD)
in the identical, mismatched unrelated, and haploidentical related cohorts were 34.6%, 33.3%, and 10.9%,
respectively. The 2-year relapse and treatment-related mortality (TRM) rates were 19.2%, 23.9%, 23.3%,
and 9.6%, 8.7%, 10% for patients who underwent identical, HLA-haploidentical related, and mismatched
unrelated transplantation, respectively. The 2-year probabilities of leukemia-free survival and overall survival
were 72.2%, 70.6%, 68.1%, and 76.5%, 77.8%, 70.0% after identical, haploidentical related and mismatched
unrelated transplantations, respectively. Multivariate analyses showed that only advanced disease stage
and a diagnosis of disease had increased risk of relapse, treatment failure, and overall mortality. In conclusion,
it is a feasible approach with acceptable outcomes for patients undergoing HLA-haploidentical related HSCT
by the combination of G-PBSCs and G-BM with conditioning regimens including ATG.
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6/j.bbmt.2008.11.029with hematologic malignancies [1]. But lack of HLA-
identical donors has restricted its application. Related
HLA-haploidentical HSCT is a viable alternative be-
cause almost every patient has at least a haplotype-
sharing parent, child, or sibling immediately available
to serve as a donor, but it has been limited by high risk
of severe graft-versus-host disease (GVHD), graft re-
jection, life-threatening infections, and relapse, which
are partially caused by intensive immunosuppressive
therapy and T cell depletion [2,3]. T cell add-back af-
ter purified HSCT decreases the risk of complications
after transplantation but cannot completely solve these
problems [4,5].
Granulocyte-colony stimulating factor-mobilized
peripheral blood stem cells (G-PBSCs) are increas-
ingly used as an alternative source of allo-HSCT to
Table 1. Patient, Donor, and Graft Characteristics
Variable
Haploidentical
Related
HSCT
Mismatched
Unrelated
HSCT
HLA-
identical
HSCT
No. of patients 46 30 52
Sex (female/male) 34/12 18/12 33/19
Median age, years (range) 25 (5-54) 28 (15-42) 30 (15-52)
Age 0 to 18 years 18 9 6
Age 19 to 35 years 16 9 35
Age older than 35 years 12 12 11
Disease
AML 15 6 12
ALL 14 12 11
CML 17 12 29
Conditioning regimens
TBI + Ara-c + CY + ATG 34 18 0
Ara-c + Bu +
CY + CCNU + ATG
12 12 0
Bu + CY 0 0 31
TBI + CY 0 0 21
ABO match
Matched 17 16 27
Minor mismatched 17 8 12
Major mismatched 12 6 13
Donor-recipient relationship
Mother to child 6 0 0
Father to child 14 0 0
Child to parent 2 0 0
Sibling 24 0 52
Unrelated 0 30 0
G-CSF use after HSCT 46 30 52
Pretransplant performance
scale (ECOG)
1 (0–2) 1 (0–2) 1 (0–2)
Disease stage
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and safety, but a higher risk GVHD was obseverd
[5,6]. Compared with G-PBSCs, granulocyte-colony
stimulating factor-mobilized bone marrow (G-BM)
resulted in reduced severity of acute GVHD
(aGVHD); moreover, G-BM transplants produced
even less chronic GVHD (cGVHD) than steady-state
bone marrow [7].
Mesenchymal stromal cells (MSCs) contained in
BM have demonstrated their abilities to modulate
GVHD pathophysiology and graft-versus-leukemia
(GVL), and possibly accelerate hematopoietic recov-
ery [8-10]. Granulocyte colony-stimulating factor
(G-CSF) markedly increased donor-derived MSCs in
the BM [11]. Several reports demonstrate accelerated
neutrophil and platelet recovery after the harvest of
G-BM for allo-HSCT [12,13]. Antithymocyte globu-
lin (ATG) may decrease the incidence of GVHD
[14]. We hypothesized that the use of combined G-
PBSCs and G-BM may result in rapid engraftment
and decrease the incidence of aGVHD and cGVHD
for patients undergoing HLA-haploidentical related
HSCT with conditioning regimens including ATG
when compared with G-PBSCs for patients undergo-
ing HLA-identical HSCT and undergoing HLA-mis-
matched unrelated HSCTwith conditioning regimens
including ATG.Chronic leukemia
CP 17 12 23
AP 0 0 4
BP 0 0 2
Acute leukemia
CR1 18 12 17
CR$2 4 3 4
PR 3 2 1
Relapse/refractory 4 1 1
AML indicates acute myeloblastic leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myoblastic leukemia; TBI, total-body irradiation;
ATG, antithymocyte globulin; CY, cyclophosphamide; Bu, busulfan;
CCNU, Lomustine; G-CSF, granulocyte-colony stimulating factor; CP,
chronic phase; AP, accelerated phase; BP, blast phase; ECOG, Eastern
Cooperative Oncology Group; CR, complete remission; PR, partial
remission; HSCT, hematopoietic stem cell transplantation.PATIENTS AND METHODS
Patients
One hundred twenty-eight patients with hemato-
logic malignancies who received an allogeneic trans-
plantation from either an HLA-identical sibling if
available (n 5 52) or an HLA-haploidentical/mis-
matched donor (n 5 76; 46 patients received haploi-
dentical-related HSCT and 30 patients received
mismatched unrelated HSCT) between 2005 and
2007 in theDepartment of Hematology, XinqiaoHos-
pital, Third Military Medical University (China) were
subjects in this study. All patients were treated by the
same attending physician staff. Our treatment protocol
was approved by the the Ethics Committee of the
Third Military Medical University, and written in-
formed consent was obtained from donors, adult pa-
tients, and from the guardians of children younger
than 18 years old. Patients were not eligible for
HSCT if they had severe liver or renal disease, cor-
rected pulmonary diffusion capacity \35%, cardiac
ejection fraction lower than 40%, Karnofsky perfor-
mance status \80, or any active infections. Table 1
summarizes the important patient characteristics. Pa-
tients were classified as having early, intermediate, or
advanced disease stages based on the status of their leu-
kemia at the time of HSCT [14]. Early-stage patients
included (1) chronic myeloid leukemia (CML) patientsin chronic phase (CP), and (2) acute myeloid leukemia
(AML) or acute lymphoblastic leukemia (ALL) in first
remission (CR1), whereas intermediate stage included
(1) CML in accelerated phase (AP), and (2) AML or
ALL in second remission (CR2). Advanced disease
stage included (1) advanced or resistant AML or
ALL, and (2) CML in blast phase (BP). Pretransplan-
tation comorbidities were noted using the Charlson
Comorbidity Index (CCI) [15]. Follow-up for all
patients went through July 30, 2008.Donor Source and HLA Disparity
HLA-A, HLA-B, and HLA-DR typing was per-
formed by serology for all donor-recipient pairs.
High-resolution DNA techniques were subsequently
Table 2. Donor-Recipient Histocompatibility
Donor
Variable Total Parent/Child Sibling Unrelated
Number 76 22 24 30
HLA-antigen class
mismatched
268 Biol Blood Marrow Transplant 15:266-273, 2009X.-h. Chen et al.performed for matched and mismatched unrelated do-
nor-recipient pairs. The degree of the locus mismatch
conforms to the China consensus on immunogenetic
donor search for transplantation full mismatch. Fifty-
two donor-recipient pairs were fully HLA matched.
Table 2 shows the HLA disparities in the cohort.Class I 27 2 1 24
Class II 15 4 5 6
Class I and Class II 34 16 18 0
No. of HLA-antigen
mismatched
1 42 6 6 30
3 34 16 18 0
No. and location
of mismatched loci
Only at HLA-A 25 1 0 24
Only at HLA-B 2 0 2 0
Only at HLA-DRB1 15 5 4 6
Mismatches at
HLA-A, -B, and -DRB1
34 16 18 0Conditioning Regimen
Two conditioning regimens were used for HLA-
haploidentical/mismathed HSCT, that is (a) Ara-c (at
a dose of 3 g/m2 every 12 hours) for 3 days combined
with intravenous (i.v.) cyclophosphamide at 50 mg/
kg/day recipient body weight for 2 consecutive days
and total-body irradiation (TBI) daily for 2 consecu-
tive days (9-9.5 Gy in total); and (b) Lomustine (120
mg/m2) for 1 day combined with busulfan (130 mg/
m2) for 3 consecutive days and cyclophosphamide (45
mg/m2) for 2 consecutive days and Ara-c (2 g/m2 every
12 hours) for 2 consecutive days. Regimen (a) was per-
formed on 48 patients and (b) on 28 patients. All pa-
tients received ATG (thymoglobuline, 5 mg/kg per
day; Fresenius, Germany) intravenously for 4 consecu-
tive days, on days 25 to 22.
Two conditioning regimens were used for HLA-
identical HSCT, that is (c) cyclophosphamide intrave-
nously at 60 mg/kg/day recipient body weight for 2
consecutive days and TBI daily for 2 consecutive
days (9-9.5 Gy in total), and (d) busulfan (0.8 mg/kg
every 6 hours) for 4 consecutive days and cyclophos-
phamide (60 mg/kg/days) for 2 consecutive days. Reg-
imen (c) was performed on 21 patients and (d) on 31
patients.
All patients received cytotoxic drugs and TBI at
a planned dose (100% 6 5%). G-CSF at a dose of 5
mg/kg was started 24 hours after transplantation, and
continued until engraftment.GVHD Prophylaxis and Management
All patients were given a combination of cyclo-
sporine A (CSA), a short course of methotrexate
(MTX), and Microphenolate Motetil (MMF).
For HLA-haploidentical/mismatched HSCT
cases, CSAwas started at a dose of 1.5mg/kg/day given
intravenously on day 27 and 2.5 mg/kg/day from day
21 when the patient was able to take the drug orally
until discharge from the hospital. CSA dose was
adjusted according to the plasma levels until day
1150 and then tapered. It was discontinued in the ab-
sence of GVHD on day 365. On day 11, MTX (15
mg/m2) was administered intravenously, and then 10
mg/m2 was given on days 13, 16, and 111, respec-
tively. MMF was begun from day 27 to day 1100 at
1 g/day. Tapering of MMF was based on the presence
or absence of severe GVHD, infectious diseases, and
relapse risk.For HLA-identical HSCT cases, CSA was started
at a dose of 1.5 mg/kg/day given intravenously on
day 27 and 2.5 mg/kg/day from day 21 when the
patient was able to take the drug orally until discharge
from the hospital. CSA dose was adjusted according to
the plasma levels until day 1100 and then tapered. It
was discontinued in the absence of GVHD on day
180. On day 11, MTX (15 mg/m2) was administered
intravenously, and then 10 mg/m2 was given on days
13 and 16, respectively. MMF was begun from day
27 to day160 at 1 g/day. Tapering ofMMFwas based
on the presence or absence of severe GVHD, infec-
tious diseases, and relapse risk.
Acute GVHD was treated with 1 to 2 mg/kg per
day of prednisolone equivalents and resumption of
full-dose CSA administration. Second-line immuno-
suppressive therapy such as tacrolimus (FK506),
MMF, and CD25 monoclonal antibody (daclizumab;
Roche, Basel, Switzerland) or MTX was given for ste-
roid refractory aGVHD.Harvest Procedures
Donor BM and/or PBSCs were collected using
standard mobilization protocols. G-CSF at a dose of
10 mg/kg body weight per day (given as a split dose
twice daily) was used subcutaneously for 5 consecutive
days. Leukapheresis was harvested on day 0 after 4 days
of G-CSF with the aid of an automated continuous
flow blood-cell separator (CS3000; Baxter, Deerfield,
IL). Apheresis was performed once in all HLA-haploi-
dentical related HSCT cases and 2 days in HLA-iden-
tical and mismatched unrelated HSCT cases. The
donor BM was harvested at room temperature in the
operation room on day 0 after 5 days of G-CSF
for HLA-haploidentical related HSCT cases. The
G-PBSCs and G-BM were transfused intravenously
to the recipients just after completion of the collec-
tion on day 1 and 2, respectively. Calcium was
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leukapheresis to reduce signs of hypocalcemia. Daily
counts and serum chemistry were obtained during
G-CSF administration, and in addition, 30 days after
the last administration of G-CSF. Donors complain-
ing of bone pain received Naproxen. Donor assess-
ments included prestudy evaluation of medical
history, physical examination, vital signs, blood chem-
istry, virology, and full blood count in accordance with
the standards of donor evaluation for allogeneic trans-
plantations [16].
Infection Prevention and Surveillance
All patients received prophylactic antibiotics when
the ANC was\0.5  109/L. Fluconazole was given to
all patients from day 215 to engraftment. Trimetho-
prim sulfamethoxazole was administered for prophy-
laxis of Pneumocystis carinii infection. Acyclovir was
given orally from days –7 to 130 and ganciclovir (5
mg/kg twice daily) was routinely administrated intra-
venously from days 27 to 22. Patients were moni-
tored weekly by cytomegalovirus (CMV) pp65
antigenemia test, and CMV-positive patients were
treated with either ganciclovir or foscarnet. Human
herpes virus 6 (HHV6), HHV7, and adenovirus were
tested by polymerase chain reaction (PCR), and herpes
simplex virus and Epstein-Barr virus by enzyme-linked
immunosorbent assay. Surveillance for bacterial, fun-
gal, Pneumocystis carinii, and other viral infections was
based on clinical requirements. Blood products were
irradiated with 2500 cGy. CMV-seronegative recipi-
ents received leucodepleted and irradiated blood prod-
ucts. When fever, severe mucositis, or new infections
occurred while on prophylaxis, additional agents
were added based on clinical status and results of path-
ogen reports.
Chimerism Analyses and Minimal Residual
Disease Monitor
Chimerism was evaluated on recipient BM cells or
peripheral blood usually on days 130, 1180, and
1365 after HSCT by cytogenetic G-banding or fluo-
rescence in situ hybridization. Sex-matched donor-
recipient chimerism was assessed by using PCR-based
analyses of polymorphic minisatellite or microsatellite
regions (variable number tandem repeat [VNTR]). As
a rule, PCR assay of BCR/ABL, IgH,WT-1, and ETO
according to the type of leukemia was used for minimal
residual disease monitoring after HSCT.
Study Design
The primary objective was to assess the feasibility
and the efficiency of ATG and G-BM in HLA-haploi-
dentical related HSCT for patients with hematologic
malignancies receiving ATG and G-PBSCs and
G-BMcomparedwith theHLA-mismatched unrelatedHSCT for patients with hematologic malignancies re-
ceiving ATG and G-PBSCs and the HLA-matched
HSCT only receiving G-PBSCs. Secondary objectives
included the assessment of chemotherapy and engraft-
ment (neutrophil and platelet), rejection, and graft fail-
ure, as well as the incidence and severity of aGVHD
and cGVHD and determination of the relapse and
mortality. Moreover, we determined the progenitor
cell yield including CD341 cell count and mononu-
clear cells (MNCs) in G-PBSCs graft and G-BM graft.
Evaluation and Definitions
CD341 cells were determined in the leukapheresis
product by flow cytometry according to our previously
described procedure [17]. Neutrophil engraftment was
defined as the first of 3 consecutive days with an abso-
lute neutrophil count (ANC) higher than 0.5  109/L.
Platelet engraftment was defined as the first of 7 con-
secutive days on which the platelet count exceeded
20  109/L without transfusions. CMV-related inter-
stitial pneumonia (IPn) was defined according to re-
ported criteria [18]. Acute GVHD was graded
according to standard criteria and assessed twice
weekly from day 130 up to day 1100 [19], and
cGVHDwas scored in accordance with the revised Se-
attle criteria in patients with at least 100 days’ survival
or follow-up [20]. Transplantation-related toxicity
(TRT) was evaluated by common toxicity criteria set
by the National Cancer Institute. Time of onset of
grades III to IV toxicities was defined as occurring
within 60 days after HSCT. Organ damage because
of GVHD and/or infectious complications was ex-
cluded. Treatment-related mortality (TRM) was de-
fined as death in the absence of relapse. Relapse was
diagnosed from BM specimens taken on day 130
and day 1100 or when clinically indicated. The dis-
ease-free survival (DFS) was calculated from trans-
plantation to the end of follow-up.
Statistical Analyses
The variables for patients receiving HLA-identical
sibling, haploidentical related donor, and mismatched
unrelated donors transplants were compared using
chi-square statistics for categoric variables and the
Kruskal-Wallis test for continuous variables. Univari-
ate probabilities of ANC and platelet engraftment,
CMV infection, aGVHD and cGVHD, TRM, and re-
lapse were calculated using cumulative incidence
curves to accommodate competing risks [21]. Table
1 showed the variables considered in multivariate anal-
ysis. The Cox proportional hazards model was used in
multivariate analyses. First, the test indicated that the
proportionality assumptions hold. The final multivar-
iate models were built using a forward stepwise model
selection approach. Eachmodel contained themain ef-
fect for HLA-haploidentical related versus HLA-
Table 3. Cell Yield (Cells/kg Recipient BodyWeight) Given in
Average Values with Minimum and Maximum in Parentheses
MNCs (108) CD34+ cells (106)
G-PBSCs graft
for matched HSCT
7.68 (5.78-14.45) 5.57 (4.69-10.89)
G-PBSCs graft
for mismatched HSCT
8.47 (6.87-15.17) 6.46 (5.01-13.99)
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versus HLA-mismatched unrelated groups. No inter-
actions were detected. Adjusted probabilities of leuke-
mia-free survival (LFS) and survival were calculated
using the multivariate models, stratified on type of
transplantation, and weighted by the pooled sample
proportion value for each prognostic factor [22].G-BM + G-PBSCs graft
for mismatched HSCT
9.25 (8.25-16.39) 7.32 (5.76-13.67)
G-PBSCs indicates granulocyte-colony stimulating factor-mobilized
peripheral blood stem cells; G-BM, granulocyte-colony stimulating
factor-mobilized bone marrow; HSCT, hematopoietic stem cell trans-
plantation; MNCs, mononuclear cells.RESULTS
Patients Characters Before Transplantation
Major characteristics of patients before transplan-
tation are shown in Table 1. Pretransplantation
comorbidities noted using the CCI showed no signifi-
cant difference among cohorts. Pretransplantation
CMV serologic analysis showed that low-risk, inter-
mediate-risk, and high-risk patients for CMV reactiv-
ity after HSCT were 11.5%, 3.8%, and 84.7%,
respectively, in the identical HSCT group, and
6.6%, 9.2%, and 84.2%, respectively, in the HLA-
haploidentical related HSCT group, and 10.0%,
6.7%, and 83.3%, respectively, in the HLA-
mismatched unrelated HSCT group, with no signifi-
cant difference between groups.
Mobilization of PBSCs, Leukapheresis,
Collection of BM, and Cell Yield in Grafts
The donors experienced only mild adverse events
(WHO grade 1 or 2). None of them revealed changes
in plasmatic clotting system parameters. The numbers
of MNCs and CD341 cells are shown in Table 3.
Hematopoietic Reconstitution
Analysis of chimerism indicated that all patients
achieved full donor chimerism by day 30 after
HSCT. All patients experienced a stable neutrophil
and platelet engraftment. There was no late graft fail-
ure. All patients engrafted to ANC exceeding 0.5 
109/L, with a median time to neutrophil engraftment
of 16 days (range: 8-26 days) in identical HSCT, 13
days (range: 10-18 days) in haploidentical related
HSCT, and 16 days (range: 9-27 days) in mismatched
unrelated HSCT (P\ .05). The platelet engraftments
in identical and haploidentical related groups at 20
days (range: 12-39 days), 19 days (range: 17-25 days),
and 19 days (range: 16-26 days) for mismatched unre-
lated group (P . .05).
GVHD Incidence and Severity
HLA-haploidentical/mismatched patients had
a higher risk for and faster rate of developing grades
I to II aGVHD than identical HSCT patients (P\
.05). The cumulative incidences of grades I to II
aGVHD on day 100 in the identical, haploidentical re-
lated, and mismatched unrelated cohorts were 21.2%,43.5%, and 53.3% (P\ .05), respectively. The cumu-
lative incidences of grades 0 were 78.8%, 56.5%, and
46.7% in the identical, haploidentical related, andmis-
matched unrelated cohorts, respectively, and grades III
to IV aGVHD on day 100 were not obseved in these
groups.
Clinical manifestation of grades I to II aGVHD in-
cluded diarrhea and vomiting, 10 (21.3%); hepatic dys-
function, 20 (42.6%); skin rash, 30 (63.8%); lung
infection, 3 (6.4%); and hemorrhagic cystitis, 1
(2.1%). Corticosteroids (1 mg/kg per day) were given
intravenously and then tapered as scheduled or based
on therapeutic response. The patients with survival
longer than 100 days after HSCT were eligible to be
evaluated for the incidence of cGVHD. Identical and
mismatched unrelated patients had higher risk of de-
veloping cGVHD. The cumulative incidences of
cGVHD in the identical, mismatched unrelated, and
haploidentical related cohorts were 34.6%, 33.3%,
and 10.9% (P\ .05), respectively.Infectious Complications and TRT
Although the patients undergoing HLA-haploi-
dentical related and unrelated HSCT had a higher
100-day cumulative incidence of CMV antigenemia
(8.7% in the haploidentical HSCT group, 6.7% in
the mismatched unrelated HSCT group, and 0% in
the identical), the incidence of CMV-associated IPn
was 0% in these groups.
Grades II to IV organ toxicities during the 60 days
after HSCT were evaluated as follows (identical, hap-
loidentical related, and mismatched unrelated cohort,
respectively): cardiovascular, 3.9%, 6.5%, and 6.7%;
neurologic, 0%, 2.2%, and 3.3%; hepatic, 7.8%,
10.7%, and 10.0%; renal, 0%, 0%, and 0%; metabo-
lism, 0%, 0%, and 0%; and hepatic veno-occlusive dis-
ease, 0%, 0%, and 0%. No deaths resulted from lethal
organ toxicities during the 60 days after HSCT.Relapse and TRM
Patients who undergoing identical, haploidentical
related, and mismatched unrelated transplantation
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analysis, the relative risk of relapse and TRM for
patients who were undergoing HLA-haploidentical
related, mismatched unrelated, and identical trans-
plantation were 0.89, 0.91, and 1.67, respectively
(P . .05). The 2-year relapse and TRM rates were
19.2%, 23.9%, 23.3%, and 9.6%, 8.7%, 10% for
patients who underdoing identical, HLA-haploidenti-
cal related, and mismatched unrelated transplantation,
respectively. Twenty-eight patients had relapsed by
the time of the last follow-up, which included 10
(19.2%) patients in the identical, 11 (23.9%) patients
in the HLA-haploidentical related, and 7 (22.3%)
patients in mismatched unrelated cohort. To treat
relapse, all patients received immunosuppressive agent
taper. Among 28 relapsed patients, 19 patients died
after relapse, 7 in the identical, 8 in the HLA-haploi-
dentical related, and 4 in mismatched unrelated
groups, with amedian time to death of 175 days (range:
147 to 387 days), 198 days (range: 129 to 285 days), and
182 days (range: 118 to 302 days), respectively. Analy-
sis of nonrelapse-related mortality showed that
aGVHD and pulmonary infection were the major
causes of death among the cohorts.
Overall Survival (OS) and Follow-up
The 2-year probabilities of LFS were 72.2%,
70.6%, and 68.1% after identical, haploidentical
related, and mismatched unrelated transplantations,
respectively. The 2-year OS probabilities were
76.5%, 77.8%, and 70.0% after identical, haploident-
ical related and mismatched unrelated transplanta-
tions, respectively. There were no differences in
survival probabilities according to disease status before
transplantation among cohorts.
Results of Multivariate Analysis for aGVHD,
cGVHD, TRM, Treatment Failure (Death in
Complete Remission or Relapse), Relapse,
and OS
Every variable listed in Table 1 was considered in
multivariate analysis. The analysis suggested that the
patients diagnosed with CML and/or in early stage
prior to HSCT had a lower incidence of relapse and
treatment failure and had a better survival.
DISCUSSION
HLA-haploidentical HSCT provides curative
treatment for hematologic malignancies. However,
the serious GVHD and delayed immune reconstitu-
tion partially restricted the practice of HLA-haploi-
dentical HSCT. HLA-haploidentical HSCT across
the histocompatibility barrier becomes possible be-
cause of more and more immunosuppressive treat-
ment. Our results showed combined G-PBSCs and
G-BM could decrease the incidence and severity ofGVHD for patients undergoing HLA-haploidentical
HSCT without T cell depletion with conditioning
regimens including ATG.
Transplantation of HLA-haploidentical BM in
myeloablated patients has been associatedwith a signif-
icant rate of engraftment failure. The combination of
cyclophosphamide, antithymocyte globulin, and thy-
mic irradiation could effectively overcome host resis-
tance to HLA-haploidentical BM engraftment [23].
Cotransplantation of MSCs could accelerate the re-
covery of hematopoiesis [24]. Rapid hematopoietic re-
covery was also observed in advanced breast cancer
patients receiving high-dose chemotherapy after the
cotransfusion of autologous peripheral blood stem
cells and culture-expanded BMSCs [25]. In this study,
all patients was successful engraftment without delay
by cotransplantation of G-PBSCs and G-BM, which
may be advantage of the quick engrftment of G-PBSCs
[5,6], and immunosuppressive role of G-BM [7], and
the use of chemotherapy and immunotherapy [23]. In
this study, the presence of MSCs contained within
the harvested BM may have contributed to the results,
but the quantities of MSCs that contained in G-BM
need testing.
The development and severity of GVHD is
strongly related with posttransplant outcomes
[26,27]. The control of GVHD is very important.
ATG has a relatively prolonged half-life in vivo. It
can be detected 30 days or even longer after its admin-
istration [28]. Thus, it potently deletes T cells long
term in vivo, preventingGVHDwith no increase in in-
cidence of relapse [29]. On the other hand, ATG in-
cluded in conditioning could result in a faster donor
chimerism after HSCT [30].
MSCs have shown to modulate the function of T
lymphocytes and NK cells involved in GVHD patho-
physiology and GVL effect [31]. MSCs from G-BM
may possess immunoregulatory activity and reduce
the incidence of GVHD [32,33]. G-PBSCs grafts
have more T-polarized cells, which modulate the cyto-
kine profile of type 2 dendritic cells and could poten-
tially protect the host from aGVHD [34-36].
Compared with G-PBSCs, the use of G-BM resulted
in comparable engraftment, reduced severity of
aGVHD; moreover, G-BM transplants produced
even less cGVHD than steady-state bone marrow
[7]. HLA-haploidentical HSCT for patients with ma-
lignant hematologic disease showed that the incidence
of GVHD is not higher in comparison with that of BM
transplantation and G-PBSCs transplantation in pa-
tients with HLA-matched donors using G-BM plus
G-PBSCs without T cell depletion ex vivo
[13,14,37,38]. In this study, our results showed that
the incidences of aGVHD is the same compared with
the previous reports [14,39], but grades III to IV
aGVHD are not observed. The cGVHD is also
much lower in the HLA-haploidentical related
272 Biol Blood Marrow Transplant 15:266-273, 2009X.-h. Chen et al.HSCT than that of the HLA-matched and mis-
matched unrelated HSCT. The reasons for decreased
incidence of severe aGVHD and cGVHDmay bemul-
tifactorial, including conditioning regimen with cyclo-
phosphamide [23] and ATG [40], the use of G-BM and
G-PBSCs [12,41], and the combination of CSA,MTX,
and MMF.
The relationship between cGVHD and aGVHD is
well established [26]. Acute GVHD is a risk factor for
the development of cGVHD, and there is also a contin-
uum from 1 syndrome to the other, with aGVHD pre-
ceding cGVHD, or aGVHD-like manifestations
developing after establishment of cGVHD. Both syn-
dromes have an impact on posttransplant survival,
and more severe clinical manifestations carry a higher
risk for mortality. In this study, the incidence of
cGVHD is much lower in patients with the HLA-hap-
loidentical related HSCT than that of identical HSCT
and mismatched unrelated HSCT, which may be an
advantage of G-BM grafts resulting in less subsequent
cGVHD [25].
GVHD is a common complication after transplan-
tation, and is shown as the primary cause of death after
HSCT. The prevention of GVHD is the emphasis of
allo-HSCT. Culture-expanded MSCs were used to al-
leviate GVHD [31]. However, culture-expanded
MSCs may be differentiation and may be contami-
nated, and result in serious serum disease after trans-
plantation. The MSCs in G-BM could not be directly
used to treat serious GVHD because of too many T
lymphocytes. G-BM containing MSCs seem to have
the role of decreasing the GVHD, which need further
testing by the purified MSCs from G-BM, which will
be the focus of our work in the next clinical practice.
Altogether, although longer follow-up and greater
numbers of patients will be required so that the po-
tency and curative potential of this approach can be as-
sessed, with the current protocol, we believed that
HLA-haploidentical related HSCTwith the combina-
tion of G-PBSCs andG-BMwith conditioning includ-
ing ATG and without T cell depletion should be
a feasible approach with an acceptable outcome.ACKNOWLEDGMENTS
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